Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2016

View Archived Issues

Alder Biopharmaceuticals initiates PROMISE 2 phase III trial

Walter Reed Army Institute of Research presents promising new malaria vaccine candidates

Ariad Pharmaceuticals patents EGFR and/or HER2 mutant inhibitors

Roche discloses HTRA1 inhibitors

Hangzhou Hertz Pharmaceutical develops BTK inhibitors

Pharmalink's Nefecon earns orphan drug designation in E.U. for IgAN

Novan reports topline results from phase II study of SB-206

Cosmo reports on phase III trial of Zemcolo for travelers' diarrhea

BromSite launched in U.S.

Idelvion launched in Japan

Ustekinumab treatment shows promise in giant cell arteritis

Cerecor reports topline data from phase II trial of CERC-301 in major depressive disorder

BLA for avelumab accepted by FDA for priority review

VBL Therapeutics reports overall survival data from phase II trial of VB-111

Results of AEGIS-I trial of CSL-112

Celldex Therapeutics completes Kolltan acquisition

QLT changes name to Novelion Therapeutics following merger with Aegerion

Evotec and Merck KGaA to collaborate on target discovery technologies

FDA grants rare pediatric disease designation to Vtesse's VTS-270

IL-1 blockade with anakinra evaluated for CPPD crystal arthritis

Arrowhead discontinues EX1-containing programs

OncoQuest reports promising interim data from phase IIb study of oregovomab in ovarian cancer

BioVie submits IND to FDA for drug to treat ascites due to liver cirrhosis

Tolerability, pharmacokinetics reported for AMG-232 in first-in-human cancer trial

EMA accepts Coherus BioSciences' MAA for pegfilgrastim biosimilar

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026